Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Fortress Biotech Inc Market Cap
From what 2 stock analysts predict, the share price for Fortress Biotech Inc (FBIO) might increase by 610.66% in the next year. This is based on a 12-month average estimation for FBIO. Price targets go from $5 to $24. The majority of stock analysts believe FBIO is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Fortress Biotech Inc has a total of 2 Wall St Analyst ratings. There are 2 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Fortress Biotech Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of FBIO.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $24 | Reiterates | Jul 19, 2024 |
| Jennifer Kim Cantor Fitzgerald | Overweight | Reiterates | Jun 20, 2024 | |
| Jason Wittes Roth MKM | Buy | $10 | Reiterates | May 16, 2024 |
Alliance Global Partners | Buy | $5 | Initiates | Mar 19, 2024 |
| Jason Wittes Roth MKM | Buy | $10 | Reinstates | Mar 15, 2024 |
| Scott Henry Roth MKM | Buy | $15 | Maintains | Nov 29, 2023 |
| Jennifer Kim Cantor Fitzgerald | Overweight | $5 | Reiterates | Aug 15, 2023 |
| Jennifer Kim Cantor Fitzgerald | Overweight | $5 | Maintains | May 16, 2023 |
| Robert Wasserman Benchmark | Speculative Buy | $5 | Reiterates | Apr 6, 2023 |
| Jeffrey Cohen Ladenburg Thalmann | Buy | $6 | Initiates | Aug 4, 2022 |
| Mayank Mamtani B. Riley Securities | Buy | $6 | Maintains | Jul 14, 2022 |
Roth Capital | Buy | $5 | Maintains | Apr 20, 2021 |
Roth Capital | Buy | $4.75 | Maintains | Oct 13, 2020 |
HC Wainwright & Co. | Buy | $10 | Maintains | Oct 12, 2020 |
Benchmark | Buy | Initiates | Oct 2, 2020 | |
| Mayank Mamtani B. Riley Securities | Buy | $6 | Maintains | Mar 13, 2020 |
B. Riley FBR | Buy | Maintains | Mar 13, 2020 | |
Cantor Fitzgerald | Overweight | Initiates | Feb 13, 2020 | |
B. Riley Securities | Buy | Initiates | Dec 18, 2019 | |
B. Riley | Buy | Initiates | Dec 18, 2019 |
When did it IPO
N/A
Staff Count
186
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Lindsay Allan Rosenwald
Market Cap
$46.8M
In 2023, FBIO generated $84.5M in revenue, which was a increase of 11.58% from the previous year. This can be seen as a signal that FBIO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 31 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Company to host conference call to discuss financial results and provide a corporate update on November 7, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on November 7, 2023 at 4:30 p.m. ET
Fri, 20 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Study demonstrated systemic exposure of DFD-29 was significantly lower than that of Solodyn (105 mg) Data presented at 43rd Annual Fall Clinical Dermatology Conference New Drug Application submission to FDA for DFD-29 anticipated in the fourth quarter of 2023 SCOTTSDALE, Ariz., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (u201cJourney Medicalu201d), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced data from a comparative bioavailability (bridging) study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs.
Mon, 16 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for which has now been accepted by the Food and Drug Administration
Mon, 09 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MIAMI, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (u201cFortressu201d or the u201cCompanyu201d), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. Fortress expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on October 10, 2023.
Thu, 05 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Fortress Biotech will present at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023, at 11:00 a.m. ET.
Thu, 07 Sep 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (u201cFortressu201d), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 11:30 a.m. ET. The Company will also attend one-on-one meetings during the conference.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
